{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:57:14Z","timestamp":1790852234078,"version":"4.1.0"},"reference-count":3,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jdin.2026.08.006","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:48:00Z","timestamp":1787932080000},"page":"124-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Trial-derived body surface area rules may restrict access to topical precision therapies in vitiligo"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2775-4525","authenticated-orcid":false,"given":"Mandisi Brendon","family":"Nkala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jdin.2026.08.006_bib1","article-title":"Ruxolitinib (Opzelura): reimbursement recommendation","volume":"5","year":"2025","journal-title":"Can J Health Technol"},{"issue":"16","key":"10.1016\/j.jdin.2026.08.006_bib2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jdin.2026.08.006_bib5","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","article-title":"Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the Global VALIANT Study","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328726001513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328726001513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:14:44Z","timestamp":1790849684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328726001513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":3,"alternative-id":["S2666328726001513"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2026.08.006","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trial-derived body surface area rules may restrict access to topical precision therapies in vitiligo","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2026.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}